All Industry articles
View all stories with this category.
-
BusinessPositive trial sets stage for therapeutic use of MDMA in US
Hallucinogen-assisted psychiatric treatment heads to regulators, amid cost and other concerns
-
BusinessTornado at Pfizer plant accentuates US drug shortage issues
Perennial problem will not be addressed without major reforms to drug market
-
BusinessLapsed US chemical security programme leaves facilities vulnerable
Chemical Facility Anti-Terrorism Standards’ expiry means rules will not be enforced, and companies cannot vet new staff
-
FeatureThe drug developers fighting the antibiotic resistance problem
Andy Extance talks to the researchers innovating across different drug classes in the hunt to develop new treatments
-
OpinionResistant to change
Curbing industrial practices that drive antimicrobial resistance needs tighter regulation and enforcement
-
BusinessHow can we maintain the effectiveness of existing antimicrobials?
Reducing environmental pollution and tackling quality issues to stave off resistance
-
FeatureWho will pay for new antibiotics?
Governments around the world are starting to consider alternative funding models and incentives for antibiotics. Katrina Megget asks if it is enough
-
OpinionSurviving in the war of all against all
Cancers and bacteria develop resistance to drugs in remarkably similar ways
-
FeatureCharting the rise in antimicrobial resistance
We look at the data behind antibiotic drug discovery and development, bacterial resistance and the financial problems with the current business model
-
OpinionCould cheap CRO rates threaten to destabilise biotech?
Pharmaceutical pipelines are heavily dependent on contract research organisations; we can’t afford for them to fail
-
BusinessFines upheld for Advanz Pharma over thyroid drug price increases
UK competition tribunal rules liothyronine pricing ’excessive’ and ‘deliberate’
-
OpinionNavigating the literature torrent
It’s humanly impossible to filter and read everything worthwhile – let’s embrace assistance
-
BusinessAntibodies face Alzheimer’s reality
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
-
BusinessBiogen to cut 1000 more jobs by 2025
Biotech giant has also agreed to buy Reata Pharmaceuticals for $7.3 billion
-
BusinessIllumina’s Grail quest results in epic fine
EU and US competition authorities object to firms completing merger without approval
-
ArticleMimicking our eyes’ sun protection
Sóliome is developing sunscreens based on natural UV-filtering peptides
-
OpinionWho knew what? And when?
Finding the line between commercially sensitive information and public and environmental protection
-
BusinessJ&J subsidiary sues more talc researchers
Lawsuit claims another study linking talc use to cancer is fraudulent
-
BusinessRevolutionising RSV prevention
New vaccines and a long-acting antibody aim to protect older adults and babies from respiratory syncytial virus
-
NewsRepercussions of Bhopal disaster found to echo on down through generations
Women pregnant in the city at the time of deadly accident gave birth to children who have higher risk of cancer